Safety Alerts & Recalls
What does this mean?
Although a linkage between lung cancer and Exubera has not been established, Pfizer has nonetheless recommended that healthcare professionals and patients should seek alternative treatment options due to the limited availability of Exubera.
Updated safety information
Pfizer today informed healthcare professionals that it has updated safety information for Exubera, a short-acting insulin used to treat patients with diabetes.
The safety information has been updated to reflect new cases of lung cancer identified in clinical trial patients using Exubera, although there were too few cases to determine whether any linkage exists between these cases and Exubera treatment. All patients who were diagnosed with lung cancer had a prior history of cigarette smoking.
For more information, please visit: more information here